Aurora Financial JournalColoplast (COLO-B.CO)
Nasdaq Copenhagen · Health care · Financial statements, TTM figures and earnings dates
In fiscal year 2025 (ended September 30, 2025), Coloplast reported revenue of DKK 27.87B and net income of DKK 3.64B. Annual financial statements are available for fiscal years 2022 to 2025, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| DKK | FY2025 2025-09-30 | FY2024 2024-09-30 | FY2023 2023-09-30 | FY2022 2022-09-30 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | DKK 27.87B | DKK 27.03B | DKK 24.50B | DKK 22.58B |
| Gross profit | DKK 18.95B | DKK 18.27B | DKK 16.33B | DKK 15.53B |
| Operating income | DKK 7.20B | DKK 7.32B | DKK 6.77B | DKK 6.44B |
| Net income | DKK 3.64B | DKK 5.05B | DKK 4.78B | DKK 4.71B |
| Diluted EPS | DKK 16.13 | DKK 22.46 | DKK 22.20 | DKK 22.11 |
| Cash flow | ||||
| Operating cash flow | DKK 6.64B | DKK 2.77B | DKK 4.23B | DKK 5.10B |
| Balance sheet | ||||
| Cash and equivalents | DKK 947.0M | DKK 788.0M | DKK 911.0M | DKK 414.0M |
| Total assets | DKK 48.37B | DKK 48.07B | DKK 48.16B | DKK 37.45B |
| Total liabilities | DKK 32.24B | DKK 30.13B | DKK 30.86B | DKK 29.15B |
| Total debt | DKK 11.57B | DKK 11.56B | DKK 16.41B | DKK 16.36B |
| Shareholders' equity | DKK 16.12B | DKK 17.94B | DKK 17.30B | DKK 8.29B |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in DKK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full COLO-B.CO page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open COLO-B.CO financials →